{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T03:00:23Z","timestamp":1768532423026,"version":"3.49.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T00:00:00Z","timestamp":1641340800000},"content-version":"vor","delay-in-days":65,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.nefroe.2022.01.002","type":"journal-article","created":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T11:37:25Z","timestamp":1643456245000},"page":"632-639","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Baseline renal functions predict the effect of canakinumab on regression of proteinuria in patients with familial Mediterranean fever"],"prefix":"10.1016","volume":"41","author":[{"given":"Tolga","family":"Yildirim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahmi","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arzu","family":"Saglam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muge","family":"Uzerk-Kibar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jabrayil","family":"Jabrayilov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunus","family":"Erdem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefroe.2022.01.002_bib0090","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1365-2249.2011.04535.x","article-title":"Immunology in clinic review series; focus on autoinflammatory diseases: role of inflammasomes in autoinflammatory syndromes","volume":"167","author":"Ozkurede","year":"2012","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.nefroe.2022.01.002_bib0095","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.semarthrit.2017.03.006","article-title":"Colchicine resistance and intolerance in familial mediterranean fever: definition, causes, and alternative treatments","volume":"47","author":"Ozen","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.nefroe.2022.01.002_bib0100","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/annrheumdis-2015-208690","article-title":"EULAR recommendations for the management of familial Mediterranean fever","volume":"75","author":"Ozen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2022.01.002_bib0105","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5152\/eurjrheum.2019.18190","article-title":"Treatment of familial mediterranean fever with canakinumab in patients who are unresponsive to colchicine","volume":"6","author":"Berdeli","year":"2019","journal-title":"Eur J Rheumatol"},{"key":"10.1016\/j.nefroe.2022.01.002_bib0110","doi-asserted-by":"crossref","first-page":"230","DOI":"10.5152\/eurjrheum.2018.18036","article-title":"IL1-blocking therapy in colchicine-resistant familial Mediterranean fever","volume":"5","author":"K\u00f6hler","year":"2018","journal-title":"Eur J Rheumatol"},{"key":"10.1016\/j.nefroe.2022.01.002_bib0115","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/RHU.0000000000000873","article-title":"Effectiveness of canakinumab in colchicine- and anakinra-resistant or -intolerant adult familial Mediterranean fever patients: a single-center real-life study","volume":"26","author":"Babaoglu","year":"2020","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.nefroe.2022.01.002_bib0120","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s40620-018-0475-5","article-title":"Canakinumab treatment in renal transplant recipients with familial Mediterranean fever","volume":"31","author":"Yildirim","year":"2018","journal-title":"J Nephrol"},{"key":"10.1016\/j.nefroe.2022.01.002_bib0125","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/acr.23446","article-title":"Nationwide experience with off-label use of interleukin-1 targeting treatment in familial Mediterranean fever patients","volume":"70","author":"Akar","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.nefroe.2022.01.002_bib0130","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/14397595.2018.1457469","article-title":"Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis","volume":"29","author":"Varan","year":"2019","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.nefroe.2022.01.002_bib0135","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1080\/14397595.2016.1194510","article-title":"Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever","volume":"27","author":"Kucuksahin","year":"2017","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.nefroe.2022.01.002_bib0140","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10753-014-0004-1","article-title":"Efficacy of interleukin-1 targeting treatments in patients with familial Mediterranean fever","volume":"38","author":"Cetin","year":"2015","journal-title":"Inflammation"},{"key":"10.1016\/j.nefroe.2022.01.002_bib0145","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40348-016-0058-2","article-title":"The experience of canakinumab in renal amyloidosis secondary to Familial Mediterranean fever","volume":"3","author":"Sozeri","year":"2016","journal-title":"Mol Cell Pediatr"},{"key":"10.1016\/j.nefroe.2022.01.002_bib0150","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10067-014-2772-2","article-title":"Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis","volume":"35","author":"\u00d6z\u00e7akar","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.nefroe.2022.01.002_bib0155","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.nefro.2015.06.026","article-title":"Anakinra induces complete remission of nephrotic syndrome in a patient with familial Mediterranean fever and amyloidosis","volume":"36","author":"Sevillano","year":"2016","journal-title":"Nefrologia"},{"key":"10.1016\/j.nefroe.2022.01.002_bib0160","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/art.1780371215","article-title":"Colchicine treatment of AA amyloidosis of familial Mediterranean fever. An analysis of factors affecting outcome","volume":"37","author":"Livneh","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nefroe.2022.01.002_bib0165","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00467-003-1129-x","article-title":"Efficacy of colchicine therapy in amyloid nephropathy of familial Mediterranean fever","volume":"18","author":"Oner","year":"2003","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nefroe.2022.01.002_bib0170","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00467-015-3249-5","article-title":"Anti-interleukin 1 treatment in secondary amyloidosis associated with autoinflammatory diseases","volume":"31","author":"Topaloglu","year":"2016","journal-title":"Pediatr Nephrol"}],"container-title":["Nefrolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251422000025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251422000025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T19:47:37Z","timestamp":1761853657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2013251422000025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S2013251422000025"],"URL":"https:\/\/doi.org\/10.1016\/j.nefroe.2022.01.002","relation":{},"ISSN":["2013-2514"],"issn-type":[{"value":"2013-2514","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baseline renal functions predict the effect of canakinumab on regression of proteinuria in patients with familial Mediterranean fever","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefroe.2022.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}